Jump to main content
Jump to site search

Issue 6, 2018
Previous Article Next Article

Tissue and plasma proteomics for early stage cancer detection

Author affiliations

Abstract

The pursuit of novel and effective biomarkers is essential in the struggle against cancer, which is a leading cause of mortality worldwide. Biomarkers can be used as specific diagnostic tools, prognostic predictors, markers of the development of therapeutic resistance or even as therapeutic targets themselves. Through the application of sensitive and specific proteomic techniques, oncoproteomics investigates the proteins associated with cancer processes, to better understand their biological function/s and their associated pathways during tumorigenesis. Such studies seek to identify both potential biomarkers and drug targets in order to improve patient survival and quality of life whilst reducing the global health budget. Tissue and plasma are the most commonly utilised biological samples for such studies as they are readily available, non-invasive and generally acceptable. Here, we outline the relative advantages and disadvantages of the most frequently used techniques for cancer diagnosis, prognosis, treatment and surveillance, concentrating on the latest advances and application of tissue and plasma proteomics for novel cancer biomarker discovery and disease surveillance.

Graphical abstract: Tissue and plasma proteomics for early stage cancer detection

Back to tab navigation

Publication details

The article was received on 30 May 2018, accepted on 10 Sep 2018 and first published on 13 Sep 2018


Article type: Review Article
DOI: 10.1039/C8MO00126J
Citation: Mol. Omics, 2018,14, 405-423
  •   Request permissions

    Tissue and plasma proteomics for early stage cancer detection

    L. Peng, D. I. Cantor, C. Huang, K. Wang, M. S. Baker and E. C. Nice, Mol. Omics, 2018, 14, 405
    DOI: 10.1039/C8MO00126J

Search articles by author

Spotlight

Advertisements